## 

			771
Date	Communication content	Communication and results	The Company's treatment results to independent directors' opinions
2022.01.19 Board of directors	• Audit of R&D, procurement and payment, supervision and management of subsidiaries, management of the process for preparing financial statements, management of assets acquired and disposed of, compliance with acts and regulations, and tracking of improvement of internal control deficiencies and unusual circumstances.	No dissent from all independent directors upon full communication upon full communication .	• Followed up by the Board of Directors
2022.03.25 Board of directors	<ul> <li>Endorsement/guarantee, loans to others, and derivatives traded.</li> <li>Proposal for the Company's 2021 Declaration of Internal Control System.</li> </ul>	<ul> <li>No dissent from all independent directors upon full communication upon full communication</li> <li>No objection from all independent directors to the report.</li> </ul>	<ul> <li>Followed up by the Board of Directors</li> <li>Passed by the board of directors as proposed</li> </ul>
2022.05.10 Board of directors	• Endorsements and guarantees, loans to others, derivatives traded, tracking of improvement of internal control deficiencies and unusual circumstances, and management of the process for preparing financial statements.	• No dissent from all independent directors upon full communication upon full communication	• Followed up by the Board of Directors
2022.08.12 Board of directors	<ul> <li>Supervision and management of the subsidiary's payroll and personnel cycle, derivatives traded, use of computerized information processing, tracking of internal control deficiencies and unusual circumstances, management of loans to others, management of endorsements or guarantees to others.</li> <li>Proposal for revising the Company's Guidelines for the Application of the Internal Control System.</li> </ul>	<ul> <li>No dissent from all independent directors upon full communication upon full communication.</li> <li>No objection from all independent directors to revising the report.</li> </ul>	<ul> <li>Followed up by the Board of Directors</li> <li>Passed by the board of directors as proposed</li> </ul>
2022.09.13 Board of	• Review of derivatives traded, management of meetings of the Audit	<ul> <li>No dissent from all</li> </ul>	• Followed up by the

Date	Communication content	Communication and results	The Company's treatment results to independent directors' opinions
directors	Committee, and management of seals.	independent directors upon full communication upon full communication	Board of Directors
2022.11.14 Board of Directors	<ul> <li>Management of the rules of procedure, management of derivatives traded, tracking of improvement of internal control deficiencies and unusual circumstances, management of loans to others, management of endorsements and guarantees for others, management of the process for preparing financial statements.</li> </ul>	No dissent from all independent directors upon full communication upon full communication	• Followed up by the Board of Directors
	<ul> <li>Proposal for further revising the Company's SOP for Revising the Internal Control System</li> </ul>	No objection from all independent directors to revising the report.	<ul> <li>Passed by the board of directors as proposed</li> </ul>
	• Proposal for the Company's 2023 Internal Audit Review Plan	• No objection from all independent directors to the plan.	• Passed by the board of directors as proposed